Dr. Reddy’s shares rose over 4% after announcing a global biosimilar partnership with Alvotech for Keytruda. Q4FY25 profit rose 22% YoY to Rs 1,594 crore. Despite 2025 YTD decline, shares gained 14% in three months. Analysts maintain a ‘Hold’ rating.
